<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1396" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1396/" /><meta name="ncbi_pagename" content="Alpha-Mannosidosis - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Alpha-Mannosidosis - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Alpha-Mannosidosis" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2019/07/18" /><meta name="citation_author" content="Dag Malm" /><meta name="citation_author" content="Øivind Nilssen" /><meta name="citation_pmid" content="20301570" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1396/" /><meta name="citation_keywords" content="α-Mannosidosis" /><meta name="citation_keywords" content="a-Mannosidosis" /><meta name="citation_keywords" content="Lysosomal alpha-mannosidase" /><meta name="citation_keywords" content="MAN2B1" /><meta name="citation_keywords" content="Alpha-Mannosidosis" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Alpha-Mannosidosis" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Dag Malm" /><meta name="DC.Contributor" content="Øivind Nilssen" /><meta name="DC.Date" content="2019/07/18" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1396/" /><meta name="description" content="Alpha-mannosidosis encompasses a continuum of clinical findings from mild to severe. Three major clinical subtypes have been suggested:" /><meta name="og:title" content="Alpha-Mannosidosis" /><meta name="og:type" content="book" /><meta name="og:description" content="Alpha-mannosidosis encompasses a continuum of clinical findings from mild to severe. Three major clinical subtypes have been suggested:" /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1396/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/a-mannosidosis/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1396/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8CCF1BE04015410000000005E901F8.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1396_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1396_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/alpha1-a/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/xlmr/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1396_"><span class="title" itemprop="name">Alpha-Mannosidosis</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonym: &#x003b1;-Mannosidosis</div><p class="contrib-group"><span itemprop="author">Dag Malm</span>, MD, PhD and <span itemprop="author">&#x000d8;ivind Nilssen</span>, PhD.</p><a data-jig="ncbitoggler" href="#__NBK1396_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1396_ai__"><div class="contrib half_rhythm"><span itemprop="author">Dag Malm</span>, MD, PhD<div class="affiliation small">Senior Consultant, Troms&#x000f8; Center of Internal Medicine<br />Troms&#x000f8;, Norway<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="on.enilno@mlam.gad" class="oemail">on.enilno@mlam.gad</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">&#x000d8;ivind Nilssen</span>, PhD<div class="affiliation small">Professor, Department of Clinical Medicine - Medical Genetics<br />University of Troms&#x000f8;<br />Senior Scientist, Division of Child and Adolescent Health<br />Department of Medical Genetics<br />University Hospital of North Norway<br />Troms&#x000f8;, Norway<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="on.tiu@nesslin.dnivio" class="oemail">on.tiu@nesslin.dnivio</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">October 11, 2001</span>; Last Revision: <span itemprop="dateModified">July 18, 2019</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="a-mannosidosis.Summary" itemprop="description"><h2 id="_a-mannosidosis_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Alpha-mannosidosis encompasses a continuum of clinical findings from mild to severe. Three major clinical subtypes have been suggested:</p><ul><li class="half_rhythm"><div>A mild form recognized after age ten years with absence of skeletal abnormalities, myopathy, and slow progression (type 1)</div></li><li class="half_rhythm"><div>A moderate form recognized before age ten years with presence of skeletal abnormalities, myopathy, and slow progression (type 2)</div></li><li class="half_rhythm"><div>A severe form manifested as prenatal loss or early death from progressive central nervous system involvement or infection (type 3)</div></li></ul><p>Individuals with a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> have mild-to-moderate intellectual disability, impaired hearing, characteristic coarse features, clinical or radiographic skeletal abnormalities, immunodeficiency, and primary central nervous system disease &#x02013; mainly cerebellar involvement causing ataxia. Periods of psychiatric symptoms are common. Associated medical problems can include corneal opacities, hepatosplenomegaly, aseptic destructive arthritis, and metabolic myopathy. Alpha-mannosidosis is insidiously progressive; some individuals may live into the sixth decade.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of alpha-mannosidosis is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of deficient acid alpha-mannosidase enzyme activity in peripheral blood leukocytes or other nucleated cells such as fibroblasts. Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>MAN2B1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can confirm the diagnosis and allow for family studies.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> The enzyme replacement therapy velmanase alfa has been approved in some European countries for treatment of alpha-mannosidosis. Treatments aimed at preventing complications and optimizing quality of life also include early use of antibiotics for bacterial infections, hearing aids for hearing loss, insertion of pressure-equalizing tubes if fluid accumulates in the middle ear, glasses to correct refractive error, physiotherapy, use of a wheelchair, orthopedic intervention, and shunting as needed for hydrocephalus. Educational considerations include use of sign language for individuals with hearing loss, early educational intervention for development of social skills, speech therapy, and special education to maximize learning.</p><p><i>Prevention of secondary complications:</i> Prophylactic vaccinations because of immunodeficiency.</p><p><i>Surveillance:</i> Annual or semiannual medical history and physical examination and specific otolaryngology, audiometry, ophthalmologic, neuropsychological, and skeletal examinations, along with blood tests and CT scans of the brain.</p><p><i>Evaluation of relatives at risk:</i> Test at-risk newborn sibs to permit early intervention for <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> children.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Alpha-mannosidosis is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives is possible if the pathogenic variants in the family are known. Prenatal testing for pregnancies at increased risk is possible by assay of acid alpha-mannosidase enzymatic activity or <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> once the pathogenic variants have been identified in the family.</p></div></div><div id="a-mannosidosis.Diagnosis"><h2 id="_a-mannosidosis_Diagnosis_">Diagnosis</h2><div id="a-mannosidosis.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Alpha-mannosidosis <b>should be suspected</b> in individuals with the following clinical, laboratory, and pathology findings.</p><p><b>Clinical features</b></p><ul><li class="half_rhythm"><div>Facial features (e.g., coarse facial features, macrocephaly, prominent forehead, highly arched brows, depressed nasal bridge, widely spaced teeth, macroglossia, prognathism)</div></li><li class="half_rhythm"><div>Skeletal abnormalities (e.g., dysostosis multiplex, focal lytic or sclerotic lesions, osteonecrosis, osteopenia)</div></li><li class="half_rhythm"><div>Hearing loss, mixed</div></li><li class="half_rhythm"><div>Frequent infections</div></li><li class="half_rhythm"><div>Developmental delay</div></li><li class="half_rhythm"><div>Intellectual disability</div></li><li class="half_rhythm"><div>Ataxia</div></li></ul><p><b>Laboratory features.</b> Elevated urinary excretion of mannose-rich oligosaccharides can be demonstrated by thin-layer chromatography [<a class="bk_pop" href="#a-mannosidosis.REF.humble.1975">Humble &#x00026; Collart 1975</a>] or capillary high-performance anion exchange chromatography [<a class="bk_pop" href="#a-mannosidosis.REF.bruggink.2012.1671">Bruggink et al 2012</a>].</p><p><b>Histopathology.</b> Light microscopy demonstrates vacuoles in lymphocytes from peripheral blood in 90% of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="a-mannosidosis.Establishing_the_Diagnosi"><h3>Establishing the Diagnosis</h3><p>The diagnosis of alpha-mannosidosis <b>can be established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> by identification of deficiency of lysosomal enzyme acid alpha-mannosidase (MAN2B1) in leukocytes or other nucleated cells. In <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, alpha-mannosidase enzyme activity in peripheral blood leukocytes is 5%-10% of normal activity. Note: This "residual" enzyme activity appears to represent mannosidase from other organelles or compartments (e.g., Golgi apparatus or cytosol) since they show some activity also at low pH.</p><p><b>Molecular genetic testing.</b> Identification of <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> pathogenic variants in <i>MAN2B1</i> by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> can establish the diagnosis (see <a class="figpopup" href="/books/NBK1396/table/a-mannosidosis.T.molecular_genetic_testi/?report=objectonly" target="object" rid-figpopup="figamannosidosisTmoleculargenetictesti" rid-ob="figobamannosidosisTmoleculargenetictesti">Table 1</a>). Approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing*</b>, use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>,</b> and <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b>.</p><p><b>* Before single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing,</b> the activity of lysosomal alpha-mannosidase should be determined.</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>MAN2B1</i> is then performed, followed by gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> if only one or no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>MAN2B1</i> and other genes of interest (see <a href="#a-mannosidosis.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests. (4) In individuals with only <i>MAN2B1</i> variants of uncertain significance identified, DNA sequencing should be followed by testing alpha-mannosidase activity in peripheral blood leukocytes.</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing.</b> When the diagnosis of alpha-mannosidosis is not considered because an individual has atypical phenotypic features, comprehensive genomic testing (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. Exome sequencing is the most commonly used genomic testing method; <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a> is also possible.</div><div class="half_rhythm">For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</div></li></ul><div id="a-mannosidosis.T.molecular_genetic_testi" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Alpha-Mannosidosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1396/table/a-mannosidosis.T.molecular_genetic_testi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-mannosidosis.T.molecular_genetic_testi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_a-mannosidosis.T.molecular_genetic_testi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_a-mannosidosis.T.molecular_genetic_testi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Method</th><th id="hd_h_a-mannosidosis.T.molecular_genetic_testi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by Method</th></tr></thead><tbody><tr><td headers="hd_h_a-mannosidosis.T.molecular_genetic_testi_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>MAN2B1</i></td><td headers="hd_h_a-mannosidosis.T.molecular_genetic_testi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_a-mannosidosis.T.molecular_genetic_testi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">98.5%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_a-mannosidosis.T.molecular_genetic_testi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5</sup></td><td headers="hd_h_a-mannosidosis.T.molecular_genetic_testi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">&#x0003c;2%&#x000a0;<sup>6</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="a-mannosidosis.TF.1.1"><p class="no_margin">See <a href="/books/NBK1396/#a-mannosidosis.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="a-mannosidosis.TF.1.2"><p class="no_margin">See <a href="#a-mannosidosis.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="a-mannosidosis.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="a-mannosidosis.TF.1.4"><p class="no_margin">More than 130 <i>MAN2B1</i> pathogenic variants have been reported [<a class="bk_pop" href="#a-mannosidosis.REF.berg.1999.77">Berg et al 1999</a>, <a class="bk_pop" href="#a-mannosidosis.REF.kuokkanen.2011.2651">Kuokkanen et al 2011</a>, <a class="bk_pop" href="#a-mannosidosis.REF.riise_stensland.2012.511">Riise Stensland et al 2012</a>]; reviewed in <a class="bk_pop" href="#a-mannosidosis.REF.riise_stensland.2015.581">Riise Stensland et al [2015]</a>.</p></div></dd><dt>5. </dt><dd><div id="a-mannosidosis.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="a-mannosidosis.TF.1.6"><p class="no_margin">A few <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals were found to have a <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of one or more exons [<a class="bk_pop" href="#a-mannosidosis.REF.riise_stensland.2012.511">Riise Stensland et al 2012</a>].</p></div></dd></dl></div></div></div></div></div><div id="a-mannosidosis.Clinical_Characteristics"><h2 id="_a-mannosidosis_Clinical_Characteristics_">Clinical Characteristics</h2><div id="a-mannosidosis.Clinical_Description"><h3>Clinical Description</h3><p>The clinical <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of alpha-mannosidosis varies considerably with a wide spectrum of clinical findings and broad variability in individual presentation. Designating clinical types can be useful in prognosis and management. At least three clinical types (mild, moderate, and severe) have been suggested [<a class="bk_pop" href="#a-mannosidosis.REF.malm.2008.21">Malm &#x00026; Nilssen 2008</a>]. Most individuals described fit into the moderate type.</p><ul><li class="half_rhythm"><div><b>Mild form.</b> Clinically recognized after age ten years, with myopathy, slow progression, and absence of skeletal abnormalities (type 1)</div></li><li class="half_rhythm"><div><b>Moderate form.</b> Clinically recognized before age ten years, with myopathy, slow progression, and presence of skeletal abnormalities (type 2)</div></li><li class="half_rhythm"><div><b>Severe form.</b> With obvious progression leading to early death from primary central nervous system involvement or infection (type 3)</div></li></ul><p><b>Motor function.</b> Affected children learn to walk somewhat later than normal. They are generally clumsy; ataxia is the most characteristic and specific motor disturbance. In addition to joint abnormalities and a metabolic myopathy [<a class="bk_pop" href="#a-mannosidosis.REF.alroy.1984.1280">Alroy et al 1984</a>], the disease particularly affects those areas of the brain responsible for fine motor function and muscular coordination. Muscular hypotonia is common. Spastic paraplegia has also been described [<a class="bk_pop" href="#a-mannosidosis.REF.kawai.1985.201">Kawai et al 1985</a>], but in general, spasticity, rigidity, and dyskinesia are not observed. Follow-up observations have also suggested progressive impairment of motor function with age [<a class="bk_pop" href="#a-mannosidosis.REF.autio.1982.93">Autio et al 1982</a>]. A longitudinal clinical study on a brother and sister indicated no progression over a period of 25 years [<a class="bk_pop" href="#a-mannosidosis.REF.ara.1999.369">Ara et al 1999</a>]. However, as their basic neuropsychological impairment was described as severe, progression would be difficult to detect.</p><p><b>Intellectual disability.</b> Early psychomotor development may appear normal, but intellectual disability occurs in all individuals. Individuals with adult-onset disease are usually mildly or moderately intellectually disabled with an IQ of 60-80 [<a class="bk_pop" href="#a-mannosidosis.REF.aylsworth.1976.814">Aylsworth et al 1976</a>, <a class="bk_pop" href="#a-mannosidosis.REF.bach.1978.1010">Bach et al 1978</a>]. The measurement of total mental performance is very complex, and individuals tend to score better in nonverbal tests. Individuals are late in initiating speech (sometimes as late as the second decade) and have restricted vocabulary and difficult-to-understand pronunciation &#x02013; possibly the results of <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> and/or later-onset hearing loss.</p><p>Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals described have been children; therefore, information on the natural course of alpha-mannosidosis is based on a limited number of observations. Some investigators suggest that intellectual disability progresses slowly [<a class="bk_pop" href="#a-mannosidosis.REF.autio.1982.93">Autio et al 1982</a>]; others suggest that disease progression ceases after puberty [<a class="bk_pop" href="#a-mannosidosis.REF.yunis.1976.841">Yunis et al 1976</a>]. In a few individuals undergoing neurodevelopmental assessment, general intelligence, language skills, visual-spatial skills, and overall adaptive abilities appeared stable over a period of two years [<a class="bk_pop" href="#a-mannosidosis.REF.noll.1989.507">Noll et al 1989</a>]. In a longitudinal study of a brother and sister over a period of 25 years, decreased speech capacity was seen in one sib but not the other [<a class="bk_pop" href="#a-mannosidosis.REF.ara.1999.369">Ara et al 1999</a>].</p><p><b>Psychiatric symptoms</b> distinct from the intellectual disability may affect 25% or more of persons with alpha-mannosidosis. Onset is typically from late puberty to early adolescence. Episodes may be recurrent and of limited duration; medication may be necessary to alleviate symptoms.</p><p>In nine individuals with alpha-mannosidosis and psychiatric symptoms, a physical or psychological stressor preceded the rapid development of confusion, delusions, hallucinations, anxiety, and often depression, leading to severe loss of function usually lasting three to 12 weeks, and followed by a period of somnolence, asthenia, and prolonged sleep [<a class="bk_pop" href="#a-mannosidosis.REF.malm.2005.865">Malm et al 2005</a>]. In four of the nine individuals, evaluation of the psychiatric syndrome did not reveal an underlying organic cause.</p><p><b>Neuroimaging.</b> Brain MRI including sagittal T<sub>1</sub> and axial T<sub>2</sub> sections reveals a partially empty sella turcica, cerebellar atrophy, and white matter signal modifications. Progressive cortico-subcortical atrophy, especially in the cerebellar vermis, has been described [<a class="bk_pop" href="#a-mannosidosis.REF.ara.1999.369">Ara et al 1999</a>]. High signal abnormalities involving the parieto-occipital white matter are identified on axial T<sub>2</sub>-weighted scans in some individuals and are probably related to demyelination and associated gliosis as described by <a class="bk_pop" href="#a-mannosidosis.REF.dietemann.1990.485">Dietemann et al [1990]</a>.</p><p><b>Hearing loss.</b> Most individuals appear to have early-childhood-onset non-progressive hearing loss. In many if not most individuals, the hearing loss is partly conductive and partly sensorineural [<a class="bk_pop" href="#a-mannosidosis.REF.autio.1982.93">Autio et al 1982</a>]. Individuals typically experience early ear infections with fluid in the middle ear, probably the result of immunodeficiency and bony abnormalities of the skull leading to closure of the eustachian tubes. If untreated in early childhood, reduced hearing contributes to disturbances in speech and mental function.</p><p><b>Facial features.</b> Independent of family and ethnicity, individuals have typical Hurler-like facies (see <a href="/books/n/gene/mps1/">Mucopolysaccharidosis Type 1</a>) or coarse facial features, macrocephaly with a prominent forehead, highly arched eyebrows, depressed nasal bridge, widely spaced teeth, macroglossia, and prognathism. The features can also be so subtle that they may be overlooked by an inexperienced observer.</p><p><b>Bone disease</b> ranges from asymptomatic osteopenia to focal lytic or sclerotic lesions and osteonecrosis. Clinical or radiographic evidence of mild-to-moderate dysostosis multiplex occurs in 90% of individuals diagnosed with alpha-mannosidosis [<a class="bk_pop" href="#a-mannosidosis.REF.chester.1982">Chester et al 1982</a>]; intrafamilial variation is considerable. Conventional radiographs (x-rays) may reveal thickened calvaria; ovoid configuration, flattening, and hook-shaped deformity of the vertebral bodies; hypoplasia of the inferior portions of the ilia; and mild expansion of the short tubular bones of the hands.</p><p>Knock-knee is common and contributes to the gait disturbance.</p><p>The skeletal abnormalities may decrease with age [<a class="bk_pop" href="#a-mannosidosis.REF.spranger.1976.401">Spranger et al 1976</a>].</p><p>Cranial MRI, including sagittal T<sub>1</sub> and axial T<sub>2</sub> sections, demonstrates several skeletal abnormalities including brachycephaly, thick calvarium, and poor pneumatization of the sphenoid body [<a class="bk_pop" href="#a-mannosidosis.REF.dietemann.1990.485">Dietemann et al 1990</a>].</p><p><b>Immunodeficiency.</b> Individuals with alpha-mannosidosis have frequent infections. <a class="bk_pop" href="#a-mannosidosis.REF.malm.2000.699">Malm et al [2000]</a> compared humoral and cellular immunocompetence in six <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals to that of six healthy controls. They determined that individuals with alpha-mannosidosis appear to have decreased ability to produce specific antibodies in response to antigen presentation. Although infections generate compensatory mechanisms in leukocytes to improve phagocytosis, these mechanisms are inadequate because of disease-induced phagocyte-blocking agents in the serum or because of the lack of specific antibodies. In addition, leukocytes have a decreased capacity for intracellular killing, which may contribute to the often serious outcome of bacterial infections.</p><p><b>Hepatosplenomegaly.</b> The liver and spleen are often enlarged, especially in more severely <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals; however, this has no clinical significance. Liver function is normal. Liver biopsy reveals the same vacuoles in hepatocytes as described in several hematologic cell lines.</p><p><b>Ocular features.</b> Hyperopia, myopia, or slight strabismus is common. Lenticular changes, superficial corneal opacities [<a class="bk_pop" href="#a-mannosidosis.REF.bach.1978.1010">Bach et al 1978</a>], and blurred discs [<a class="bk_pop" href="#a-mannosidosis.REF.kjellman.1969.366">Kjellman et al 1969</a>] have been reported. Most of these ophthalmologic findings can be remedied (see <a href="#a-mannosidosis.Management">Management</a>).</p><p><b>Other</b></p><ul><li class="half_rhythm"><div>Communicating hydrocephalus can occur at any age [<a class="bk_pop" href="#a-mannosidosis.REF.halperin.1984.777">Halperin et al 1984</a>].</div></li><li class="half_rhythm"><div>Cardiac and renal complications are rarely observed; however, aortic regurgitation may be more common in individuals with alpha-mannosidosis.</div></li><li class="half_rhythm"><div>Systemic lupus erythematosus has been frequently observed in individuals with alpha-mannosidosis.</div></li></ul><p><b>Natural course of the disease.</b> The first decade of life is characterized by a high incidence of recurrent infections, including the common cold, pneumonia, gastroenteritis, and more rarely, infections of the urinary tract. Serous otitis media is common and is usually not bacterial.</p><p>The infections diminish in the second and third decade, when ataxia and muscular weakness are more prominent. However, many individuals are able to ski, ride a bike, or play soccer up to the third decade. At any time, individuals risk setbacks in the form of acute necrotizing arthritis or acute hydrocephalus, both requiring surgery. Worsening of the myopathy has also been described [<a class="bk_pop" href="#a-mannosidosis.REF.kawai.1985.201">Kawai et al 1985</a>, unpublished personal data].</p><p><b>Pathophysiology.</b> During normal turnover and catabolism, glycoproteins are digested by proteinases and glycosidases within the lysosomes. These enzymes degrade glycoproteins into fragments small enough to be excreted or transported to the cytosol for reuse. Lack or deficiency of a hydrolase, such as lysosomal alpha-mannosidase, results in the multisystemic accumulation of undigested oligosaccharides in the lysosomes. However, the pathophysiology of lysosomal storage disorders is complex, and accumulation of storage material alone cannot fully explain disease mechanisms.</p></div><div id="a-mannosidosis.GenotypePhenotype_Correla"><h3>Genotype-Phenotype Correlations</h3><p>No <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> are known.</p></div><div id="a-mannosidosis.Nomenclature"><h3>Nomenclature</h3><p>Alpha-mannosidosis may also be referred to as "lysosomal alpha-d-mannosidase deficiency."</p></div><div id="a-mannosidosis.Prevalence"><h3>Prevalence</h3><p>Little is known about the prevalence of alpha-mannosidosis. A study from Australia reported a prevalence of one in 500,000 [<a class="bk_pop" href="#a-mannosidosis.REF.meikle.1999.249">Meikle et al 1999</a>]. A study from Norway reported six individuals in a population of 4.5 million [<a class="bk_pop" href="#a-mannosidosis.REF.malm.1995.594">Malm et al 1995</a>], and a prevalence of one in 300,000 was reported in the Czech Republic [<a class="bk_pop" href="#a-mannosidosis.REF.poupetov_.2010.387">Poupetov&#x000e1; et al 2010</a>].</p><p>The disease is not specific to any ethnic group; individuals from all parts of the world have been described [<a class="bk_pop" href="#a-mannosidosis.REF.riise_stensland.2012.511">Riise Stensland et al 2012</a>].</p></div></div><div id="a-mannosidosis.Genetically_Related_Allel"><h2 id="_a-mannosidosis_Genetically_Related_Allel_">Genetically Related (Allelic) Disorders</h2><p>No phenotypes other than those discussed in this <i>GeneReview</i> are known to be associated with pathogenic variants in <i>MAN2B1</i>.</p></div><div id="a-mannosidosis.Differential_Diagnosis"><h2 id="_a-mannosidosis_Differential_Diagnosis_">Differential Diagnosis</h2><p><b>Lysosomal storage disease.</b> The main clinical features in alpha-mannosidosis &#x02013; intellectual disability, ataxia, coarse face, and dysostosis multiplex &#x02013; may show overlap with other lysosomal storage diseases (e.g., <a href="/books/n/gene/mps1/">mucopolysaccharidosis type 1</a>). However, the distinctive clinical features associated with these other lysosomal storage diseases, the availability of biochemical testing in clinical laboratories, and an understanding of their natural history should help in distinguishing between them.</p><div id="a-mannosidosis.T.disorders_to_consider_i" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of Alpha-Mannosidosis</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1396/table/a-mannosidosis.T.disorders_to_consider_i/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-mannosidosis.T.disorders_to_consider_i_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical and Laboratory Features of This Disorder</th></tr><tr><th headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4" id="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/&#x003b1;-mannosidosis</th><th headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4" id="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from &#x003b1;-mannosidosis</th></tr></thead><tbody><tr><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mucopolysaccharidoses (see <a href="/books/n/gene/mps1/">MPS I</a>)</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Many</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR<br />XL</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coarse facial features, dysostosis multiplex, ID</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Short stature, contractures</td></tr><tr><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sialidosis<br />(OMIM <a href="https://omim.org/entry/256550" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">256550</a>)</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NEU1</i></td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coarse facial features, dysostosis multiplex, ID</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Cherry red spot of the macula</td></tr><tr><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mucolipidosis II (see <a href="/books/n/gene/ml2/"><i>GNPTAB</i>-Related Disorders</a>)</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GNPTAB</i></td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coarse facial features, dysostosis multiplex</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Short stature, failure to thrive</td></tr><tr><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Mucolipidosis III alpha/beta (see <a href="/books/n/gene/ml2/"><i>GNPTAB</i>-Related Disorders</a>)</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GNPTAB</i></td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coarse facial features, dysostosis multiplex</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Short stature, normal to mildly impaired cognitive development</td></tr><tr><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/cantu/">Cant&#x000fa; syndrome</a></td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>ABCC9</i><br /><i>KCNJ8</i></td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Coarse facial features, thickened ribs</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Heart defects, hypertrichosis</td></tr><tr><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sialuria<br />(OMIM <a href="http://omim.org/entry/269921" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">269921</a>)</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GNE</i></td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Hypotonia, coarse facial features, DD, frequent upper-respiratory infections</td><td headers="hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_1_4 hd_h_a-mannosidosis.T.disorders_to_consider_i_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Joint stiffness, seizures, microcytic anemia</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; DD = developmental delay; ID = intellectual disability; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; XL = <a class="def" href="/books/n/gene/glossary/def-item/x-linked/">X-linked</a></p></div></dd></dl></div></div></div></div><div id="a-mannosidosis.Management"><h2 id="_a-mannosidosis_Management_">Management</h2><div id="a-mannosidosis.Evaluations_Following_Ini"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with alpha-mannosidosis, the evaluations summarized in this section (if not performed as part of the evaluation that led to the diagnosis) are recommended:</p><ul><li class="half_rhythm"><div><b>Medical history</b> including evidence of hearing loss, irritability, depression; change in social, domestic, school- or work-related activities or in ability to walk distances; diarrhea or incontinence, muscle pain, joint aches, reduced range of movement, and bone pain</div></li><li class="half_rhythm"><div><b>Physical examination</b> including otoscopy, ophthalmoscopy, assessment of liver and spleen size, auscultation of heart and lungs, neurologic status including gait, and orthopedic evaluation including joint range of motion. In children, attention to growth (plot height, weight, and especially head circumference using standardized growth charts)</div></li><li class="half_rhythm"><div><b>Examination by an otolaryngologist</b> to detect impaired hearing and middle-ear infections</div></li><li class="half_rhythm"><div><b>Audiometry.</b> If intellectual disability or young age makes cooperation difficult, brain stem evoked response testing</div></li><li class="half_rhythm"><div><b>Ophthalmologic examination</b> to evaluate for corneal opacities, myopia, hyperopia, and strabismus</div></li><li class="half_rhythm"><div><b>Neuropsychological testing</b> to establish functional level and learning capacity</div></li><li class="half_rhythm"><div><b>Blood tests.</b> Clinical examination and immunologic tests (e.g., antinuclear antibodies, anti-ds-DNA antibodies) to exclude systemic lupus erythematosus (SLE)</div></li><li class="half_rhythm"><div><b>Skeletal assessment.</b> Plain radiographs of the head, knees (anterior-posterior view), spine (lateral view), and any symptomatic sites</div></li><li class="half_rhythm"><div><b>Bone densitometry</b> to detect osteopenia or osteoporosis in older individuals</div></li><li class="half_rhythm"><div><b>CT scan of the brain</b> to evaluate the size of the ventricles and shape and size of the cerebellum, particularly if signs and symptoms of hydrocephalus are present (e.g., headache, increasing gait ataxia, nausea, papilledema)</div></li><li class="half_rhythm"><div><b>Consultation</b> with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="a-mannosidosis.Treatment_of_Manifestatio"><h3>Treatment of Manifestations</h3><p><b>Enzyme replacement therapy (ERT).</b> Velmanase alfa has been developed as a treatment for alpha-mannosidosis. Improvement in both biochemical and functional parameters have been reported [<a class="bk_pop" href="#a-mannosidosis.REF.borgwardt.2018.1215">Borgwardt et al 2018</a>, <a class="bk_pop" href="#a-mannosidosis.REF.lund.2018.1225">Lund et al 2018</a>]. ERT with velmanase alfa was approved by the European Medical Agency in July 2018. Velmanase alfa has been very well tolerated and is now regarded as a standard treatment for alpha-mannosidosis.</p><p>Note: ERT has been studied extensively as a treatment for alpha-mannosidosis. The effects of ERT in knockout mice could be seen in both thin layer chromatography and histology. At lower doses, the clearing of oligosaccharides in spleen and kidney tissue was obvious, but not in brain. However, with increased enzyme doses there was also an effect both in the peripheral and central nervous system. In addition to reduced brain pathology, the mice showed reduced ataxia on treadmill testing. Although only a stabilization of findings was expected, a significant improvement both on pathologic and clinical parameters was observed in the animals [<a class="bk_pop" href="#a-mannosidosis.REF.damme.2015.987">Damme et al 2015</a>, <a class="bk_pop" href="#a-mannosidosis.REF.stroobants.2017.255">Stroobants et al 2017</a>].</p><p>Some <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals, including those who have had bone marrow transplantation (BMT), may require symptomatic treatment. The overall aim is to prevent complications and to optimize quality of life.</p><p><b>Medical measures</b></p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Early use of antibiotics</b> for bacterial infections. A clinical consequence of the immunodeficiency is that bacterial and viral infections must be treated with vigilance.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Hearing aids</b> as early as possible for individuals with sensorineural hearing loss to improve hearing and enhance speech development and social functioning</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Insertion of PE (pressure-equalizing) tubes</b> to reduce the conductive/mechanical component of hearing loss from fluid in the middle ear</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Glasses (spectacles)</b> to correct refractive error to improve vision. Although lens replacement for cataract is a standard procedure in alpha-mannosidosis, corneal transplantation can be difficult; postoperative complications include astigmatism (which may be correctable with repeat surgery, laser treatment, or optical devices).</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Physiotherapy</b> including hydrotherapy to avoid strain on the joints</div></li><li class="half_rhythm"><div class="half_rhythm">Use of a wheelchair if necessary</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Treatment of osteoporosis or osteopenia</b> identified on bone densitometry with palmidronate (Aredia<sup>&#x000ae;</sup>) monthly or zoledronic acid (Aclasta<sup>&#x000ae;</sup>) once a year</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Orthopedic intervention</b> if necessary. Special shoes may help with ankle and foot support.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Ventriculocaval shunt</b> for communicating hydrocephalus</div><div class="half_rhythm">Note: Ventriculoperitoneal shunts may cause ascites because of the reduced absorptive capacity of the peritoneal cavity [Malm, personal communication]. Therefore, ventriculocaval shunts are preferred.</div></li></ul><p><b>Educational opportunities / social considerations</b></p><ul><li class="half_rhythm"><div><b>Use of sign language</b> in individuals with significant hearing loss</div></li><li class="half_rhythm"><div><b>Early educational intervention</b> for development of social skills</div></li><li class="half_rhythm"><div><b>Speech therapy</b> to improve speech</div></li><li class="half_rhythm"><div><b>Special education</b> to maximize learning</div></li><li class="half_rhythm"><div><b>Planning housing</b> for possible future wheelchair use</div></li></ul></div><div id="a-mannosidosis.Prevention_of_Primary_Man"><h3>Prevention of Primary Manifestations</h3><p>Most <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals are clinically normal at birth. Since alpha-mannosidosis can be treated with BMT, and possibly also by ERT in the future, there is a pressing need for <a class="def" href="/books/n/gene/glossary/def-item/newborn-screening/">newborn screening</a> to identify affected individuals early, before the onset of severe irreversible pathology [<a class="bk_pop" href="#a-mannosidosis.REF.meikle.2006.307">Meikle et al 2006</a>].</p></div><div id="a-mannosidosis.Prevention_of_Secondary_C"><h3>Prevention of Secondary Complications</h3><p>Because of immunodeficiency, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals should be included in prophylactic vaccination programs.</p><p>The tendency to develop caries as a result of poor tooth quality can be reversed or delayed by good tooth hygiene or dental support [Malm, personal observation].</p><p>Regular physiotherapy to increase muscle strength may help compensate for the slowly progressive ataxia [Malm, personal observation].</p></div><div id="a-mannosidosis.Surveillance"><h3>Surveillance</h3><p>Suggested serial monitoring to evaluate severity and rate of disease progression:</p><ul><li class="half_rhythm"><div><b>Medical history</b> (annually) including number and type of infections, hearing, weight, development, irritability, depression, change in social, domestic, school- or work-related activities, ability to walk distances, diarrhea, muscle pain, joint aches or reduced range of movement, and bone pain</div></li><li class="half_rhythm"><div><b>Physical examination</b> (annually) including otoscopy, ophthalmoscopy, heart and lungs, joint range of motion, gait, neurologic status, and orthopedic evaluation. In children, attention to growth (height, weight, and especially head circumference using standardized growth charts)</div></li><li class="half_rhythm"><div><b>Examination by an otolaryngologist</b> to detect impaired hearing and middle-ear infections</div></li><li class="half_rhythm"><div><b>Audiometry.</b> If intellectual disability makes cooperation difficult, brain stem evoked response testing</div></li><li class="half_rhythm"><div><b>Ophthalmologic examination</b> to detect corneal opacities, myopia, hyperopia, and strabismus</div></li><li class="half_rhythm"><div><b>Neuropsychological testing</b> to establish functional level and learning capacities</div></li><li class="half_rhythm"><div><b>Blood tests.</b> PLOT and C-reactive protein in case of inflammation, serum concentrations of alanine aminotransferase for evaluation of concomitant liver disease, and creatinine for assessment of renal function. Immunologic status, focusing on SLE, is recommended.</div></li><li class="half_rhythm"><div><b>Skeletal assessment.</b> Plain radiographs of the head, knees (anterior-posterior view), spine (lateral view), and any symptomatic sites</div></li><li class="half_rhythm"><div><b>Bone densitometry</b> every two to five years to assess osteopenia</div></li></ul></div><div id="a-mannosidosis.Evaluation_of_Relatives_a"><h3>Evaluation of Relatives at Risk</h3><p>At-risk sibs should be tested either prenatally or in the newborn period as they will benefit from early intervention (see <a href="#a-mannosidosis.Treatment_of_Manifestatio">Treatment of Manifestations</a>).</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the pathogenic variants in the family are known;</div></li><li class="half_rhythm"><div>Assay of acid alpha-mannosidase enzyme activity in leukocytes or other nucleated cells if the pathogenic variants in the family are not known.</div></li></ul><p>See <a href="#a-mannosidosis.Related_Genetic_Counselin">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="a-mannosidosis.Therapies_Under_Investiga"><h3>Therapies Under Investigation</h3><p><b>Bone marrow transplantation (BMT)</b> has been tried as a treatment for alpha-mannosidosis. Early diagnosis and prompt treatment with BMT increases the chances of preventing cognitive decline and improving symptoms. However, more research is necessary to determine the long-term safety and efficacy of this potential therapy. BMT is not without drawbacks. The procedure carries the risk of serious complications including graft-versus-host disease (GVHD) and other long-term and late effects as described by <a class="bk_pop" href="#a-mannosidosis.REF.mynarek.2012.352">Mynarek et al [2012]</a>. Two of 17 individuals died of procedure-related causes, two developed severe GVHD, and six developed chronic GVHD. After BMT, <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals made developmental progress, although normal development was not achieved. The perfect donor is <a class="def" href="/books/n/gene/glossary/def-item/familial/">familial</a> HLA-identical, but often this type of donor cannot be identified, in which case enzyme replacement therapy (ERT) will be the best option.</p><p><b>Gene therapy</b> is also being studied as a possible therapy for some lysosomal storage disorders. Given the permanent transfer of the normal <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, which can produce active enzyme, this form of therapy is theoretically most likely to lead to a cure. However, at this time, there are many technical difficulties to resolve before <a class="def" href="/books/n/gene/glossary/def-item/gene-therapy/">gene therapy</a> can succeed.</p><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.clinicaltrialsregister.eu/ctr-search/search" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">EU Clinical Trials Register</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div><div id="a-mannosidosis.Other"><h3>Other</h3><p>Because of the limited number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with psychiatric symptoms, no conclusion about the benefit of various psychotropic drugs can be made at this time. However, to date, olanzapine 5-15 mg at bedtime, has been used in several affected individuals with some success [Malm, unpublished observations].</p></div></div><div id="a-mannosidosis.Genetic_Counseling"><h2 id="_a-mannosidosis_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="a-mannosidosis.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Alpha-mannosidosis is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="a-mannosidosis.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> are obligate heterozygotes (i.e., carriers of one <i>MAN2B1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Affected sibs (with identical pathogenic variants) may present with different phenotypes [<a class="bk_pop" href="#a-mannosidosis.REF.riise_stensland.2012.511">Riise Stensland et al 2012</a>, <a class="bk_pop" href="#a-mannosidosis.REF.govender.2014.131">Govender &#x00026; Mubaiwa 2014</a>].</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Unless an individual with alpha-mannosidosis has children with an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual or a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, his/her offspring will be obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>MAN2B1</i>.</p><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>MAN2B1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="a-mannosidosis.Carrier_Heterozygote_Dete"><h3>Carrier (Heterozygote) Detection</h3><p><b>Molecular genetic testing</b></p><ul><li class="half_rhythm"><div>Carrier testing is most informative if the pathogenic variants have been identified in the family.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>MAN2B1</i> to the reproductive partner of a person with alpha-mannosidosis.</div></li></ul><p><b>Biochemical testing.</b> When <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> is unavailable or has been uninformative, some laboratories may offer <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> by enzyme analysis. Note, however, that acid alpha-mannosidase activity is usually 40%-60% of normal in carriers, and thus values in carriers and non-carriers sometimes overlap.</p></div><div id="a-mannosidosis.Related_Genetic_Counselin"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#a-mannosidosis.Evaluation_of_Relatives_a">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="a-mannosidosis.Prenatal_Testing_and_Prei"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p><b>Molecular genetic testing.</b> Once both <i>MAN2B1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, molecular genetic prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p><b>Biochemical testing,</b> by analysis of acid alpha-mannosidase enzymatic activity in fetal cells, is an option if genetic data are not available.</p><p>Note: Given the wide variability in <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> and lack of <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-phenotype correlation, severity of disease cannot be predicted based on the results of molecular genetic or biochemical testing.</p></div></div><div id="a-mannosidosis.Resources"><h2 id="_a-mannosidosis_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>International Advocate for Glycoprotein Storage Diseases (ISMRD)</b></div><div>3921 Country Club Drive</div><div>Lakewood CA 90712</div><div><b>Email:</b> info@ismrd.org</div><div><a href="http://www.ismrd.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ismrd.org</a></div></li><li class="half_rhythm"><div><b>Metabolic Support UK</b></div><div>5 Hilliards Court, Sandpiper Way</div><div>Chester Business Park</div><div>Chester CH4 9QP </div><div>United Kingdom</div><div><b>Phone:</b> 0845 241 2173</div><div><b>Email:</b> contact@metabolicsupportuk.org</div><div><a href="https://www.metabolicsupportuk.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.metabolicsupportuk.org</a></div></li><li class="half_rhythm"><div><b>National MPS Society</b></div><div>PO Box 14686</div><div>Durham NC 27709-4686</div><div><b>Phone:</b> 877-677-1001 (toll-free); 919-806-0101</div><div><b>Fax:</b> 919-806-2055</div><div><b>Email:</b> info@mpssociety.org</div><div><a href="http://www.mpssociety.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mpssociety.org</a></div></li></ul></div><div id="a-mannosidosis.Molecular_Genetics"><h2 id="_a-mannosidosis_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="a-mannosidosis.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Alpha-Mannosidosis: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1396/table/a-mannosidosis.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-mannosidosis.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_a-mannosidosis.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_a-mannosidosis.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_a-mannosidosis.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_a-mannosidosis.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_a-mannosidosis.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_a-mannosidosis.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_a-mannosidosis.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4125" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>MAN2B1</i></a></td><td headers="hd_b_a-mannosidosis.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4125" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">19p13<wbr style="display:inline-block"></wbr>​.13</a></td><td headers="hd_b_a-mannosidosis.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/O00754" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Lysosomal alpha-mannosidase</a></td><td headers="hd_b_a-mannosidosis.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/MAN2B1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAN2B1 database</a></td><td headers="hd_b_a-mannosidosis.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=MAN2B1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAN2B1</a></td><td headers="hd_b_a-mannosidosis.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=MAN2B1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">MAN2B1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="a-mannosidosis.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="a-mannosidosis.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Alpha-Mannosidosis (<a href="/omim/248500,609458" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1396/table/a-mannosidosis.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-mannosidosis.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/248500" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">248500</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MANNOSIDOSIS, ALPHA B, LYSOSOMAL; MANSA</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/609458" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">609458</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MANNOSIDASE, ALPHA, CLASS 2B, MEMBER 1; MAN2B1</td></tr></tbody></table></div></div><div id="a-mannosidosis.Molecular_Pathogenesis"><h3>Molecular Pathogenesis</h3><p><b>Introduction</b></p><ul><li class="half_rhythm"><div>Alpha-mannosidosis belongs to a group of disorders called glycoproteinoses.</div></li><li class="half_rhythm"><div>They are caused by lack of one of the many enzymes required for the sequential degradation of asparagine-linked oligosaccharides from glycoproteins in the lysosomes.</div></li><li class="half_rhythm"><div>Lack of any one of these enzymes, including alpha-mannosidase, will compromise the degradation pathway as a whole, resulting in accumulation of oligosaccharides or glycopeptides in the lysosomes.</div></li><li class="half_rhythm"><div>Accumulation of storage material is thought to impair lysosomal function and thereby harm cellular functions such as vesicle maturation, endocytosis, exocytosis, and calcium homeostasis [<a class="bk_pop" href="#a-mannosidosis.REF.schultz.2011.401">Schultz et al 2011</a>].</div></li></ul><p><b>Mechanism of disease causation.</b> All known <i>MAN2B1</i> pathogenic variants are predicted to result in loss of alpha-mannosidase function. The <a href="https://apex.jupiter.no/apex/f?p=101:1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">alpha-Mannosidosis Mutation Database</a> compiles genotypes, clinical phenotypes, demography, and biochemical and structural data of mutated <i>MAN2B1</i> in alpha-mannosidosis [<a class="bk_pop" href="#a-mannosidosis.REF.riise_stensland.2015.581">Riise Stensland et al 2015</a>].</p><div id="a-mannosidosis.T.notable_man2b1_pathogen" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Notable <i>MAN2B1</i> Pathogenic Variants</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1396/table/a-mannosidosis.T.notable_man2b1_pathogen/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__a-mannosidosis.T.notable_man2b1_pathogen_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_a-mannosidosis.T.notable_man2b1_pathogen_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th><th id="hd_h_a-mannosidosis.T.notable_man2b1_pathogen_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change</th><th id="hd_h_a-mannosidosis.T.notable_man2b1_pathogen_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change</th><th id="hd_h_a-mannosidosis.T.notable_man2b1_pathogen_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Comment</th></tr></thead><tbody><tr><td headers="hd_h_a-mannosidosis.T.notable_man2b1_pathogen_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000528.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000528<wbr style="display:inline-block"></wbr>​.3</a><br /><a href="https://www.ncbi.nlm.nih.gov/protein/NP_000519.2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000519<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_h_a-mannosidosis.T.notable_man2b1_pathogen_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.2248C&#x0003e;T</td><td headers="hd_h_a-mannosidosis.T.notable_man2b1_pathogen_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Arg750Trp</td><td headers="hd_h_a-mannosidosis.T.notable_man2b1_pathogen_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Founder variant accounting for 27% of pathogenic alleles in the European population&#x000a0;<sup>1</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin"><i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="a-mannosidosis.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#a-mannosidosis.REF.riise_stensland.2012.511">Riise Stensland et al [2012]</a>, <a class="bk_pop" href="#a-mannosidosis.REF.riise_stensland.2015.581">Riise Stensland et al [2015]</a></p></div></dd></dl></div></div></div></div></div><div id="a-mannosidosis.References"><h2 id="_a-mannosidosis_References_">References</h2><div id="a-mannosidosis.Published_Guidelines__Con"><h3>Published Guidelines / Consensus Statements</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.guffon.2019.470">Guffon N, Tylki-Szymanska A, Borgwardt L, Lund AM, Gil-Campos M, Parini R, Hennermann JB. Recognition of alpha-mannosidosis in paediatric and adult patients: Presentation of a diagnostic algorithm from an international working group. <span><span class="ref-journal">Mol Genet Metab. </span>2019;<span class="ref-vol">126</span>:470–4.</span> [<a href="/pubmed/30792122" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30792122</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.nilssen.2011.19">Nilssen &#x000d8;, Stensland HM, Malm D. Clinical utility gene card for: &#x003b1;-mannosidosis. <span><span class="ref-journal">Eur J Hum Genet. </span>2011:19.</span> [<a href="/pmc/articles/PMC3137507/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3137507</span></a>] [<a href="/pubmed/21368911" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21368911</span></a>]</div></li></ul></div><div id="a-mannosidosis.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.alroy.1984.1280">Alroy J, Orgad U, Ucci AA, Pereira ME. Identification of glycoprotein storage diseases by lectins: a new diagnostic method. <span><span class="ref-journal">J Histochem Cytochem. </span>1984;<span class="ref-vol">32</span>:1280–4.</span> [<a href="/pubmed/6501863" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6501863</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.ara.1999.369">Ara JR, Mayayo E, Marzo ME, Guelbenzu S, Chabas A, Pina MA, Calderon C. Neurological impairment in alpha-mannosidosis: a longitudinal clinical and MRI study of a brother and sister. <span><span class="ref-journal">Childs Nerv Syst. </span>1999;<span class="ref-vol">15</span>:369–71.</span> [<a href="/pubmed/10447604" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10447604</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.autio.1982.93">Autio S, Louhimo T, Helenius M. The clinical course of mannosidosis. <span><span class="ref-journal">Ann Clin Res. </span>1982;<span class="ref-vol">14</span>:93–7.</span> [<a href="/pubmed/7149616" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7149616</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.aylsworth.1976.814">Aylsworth AS, Taylor HA, Stuart CM, Thomas GH. Mannosidosis: phenotype of a severely affected child and characterization of alpha-mannosidase activity in cultured fibroblasts from the patient and his parents. <span><span class="ref-journal">J Pediatr. </span>1976;<span class="ref-vol">88</span>:814–8.</span> [<a href="/pubmed/5584" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 5584</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.bach.1978.1010">Bach G, Kohn G, Lasch EE, El Massri M, Ornoy A, Sekeles E, Legum C, Cohen MM. A new variant of mannosidosis with increased residual enzymatic activity and mild clinical manifestation. <span><span class="ref-journal">Pediatr Res. </span>1978;<span class="ref-vol">12</span>:1010–5.</span> [<a href="/pubmed/724292" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 724292</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.berg.1999.77">Berg T, Riise HM, Hansen GM, Malm D, Tranebjaerg L, Tollersrud OK, Nilssen O. Spectrum of mutations in alpha-mannosidosis. <span><span class="ref-journal">Am J Hum Genet. </span>1999;<span class="ref-vol">64</span>:77–88.</span> [<a href="/pmc/articles/PMC1377705/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377705</span></a>] [<a href="/pubmed/9915946" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9915946</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.borgwardt.2018.1215">Borgwardt L, Guffon N, Amraoui Y, Dali CI, De Meirleir L, Gil-Campos M, Heron B, Geraci S, Ardig&#x000f2; D, Cattaneo F, Fogh J, Van den Hout JMH, Beck M, Jones SA, Tylki-Szymanska A, Haugsted U, Lund AM. Efficacy and safety of Velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial. <span><span class="ref-journal">J Inherit Metab Dis. </span>2018;<span class="ref-vol">41</span>:1215–23.</span> [<a href="/pmc/articles/PMC6326984/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6326984</span></a>] [<a href="/pubmed/29846843" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29846843</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.bruggink.2012.1671">Bruggink C, Poorthuis BJ, Deelder AM, Wuhrer M. Analysis of urinary oligosaccharides in lysosomal storage disorders by capillary high-performance anion-exchange chromatography-mass spectrometry. <span><span class="ref-journal">Anal Bioanal Chem. </span>2012;<span class="ref-vol">403</span>:1671–83.</span> [<a href="/pmc/articles/PMC3354319/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3354319</span></a>] [<a href="/pubmed/22526647" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22526647</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.chester.1982">Chester MA, Lundblad A, &#x000d6;ckerman PA, Autio S. Mannosidosis. In: Durand P, O'Brian J, eds. <em>Genetic Errors of Glycoprotein Metabolism</em>. Milan, Italy: Edi-Ermes; 1982:89-120.</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.damme.2015.987">Damme M, Stroobants S, L&#x000fc;demann M, Rothaug M, L&#x000fc;llmann-Rauch R, Beck HC, Ericsson A, Andersson C, Fogh J, D'Hooge R, Saftig P, Blanz J. Chronic enzyme replacement therapy ameliorates neuropathology in alpha-mannosidosis mice. <span><span class="ref-journal">Ann Clin Transl Neurol. </span>2015;<span class="ref-vol">2</span>:987–1001.</span> [<a href="/pmc/articles/PMC4693626/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4693626</span></a>] [<a href="/pubmed/26817023" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26817023</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.dietemann.1990.485">Dietemann JL, Filippi de la Palavesa MM, Tranchant C, Kastler B. MR findings in mannosidosis. <span><span class="ref-journal">Neuroradiology. </span>1990;<span class="ref-vol">32</span>:485–7.</span> [<a href="/pubmed/2287376" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2287376</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.govender.2014.131">Govender R, Mubaiwa L. Alpha-mannosidosis: a report of 2 siblings and review of the literature. <span><span class="ref-journal">J Child Neurol. </span>2014;<span class="ref-vol">29</span>:131–4.</span> [<a href="/pubmed/23307885" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23307885</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.halperin.1984.777">Halperin JJ, Landis DM, Weinstein LA, Lott IT, Kolodny EH. Communicating hydrocephalus and lysosomal inclusions in mannosidosis. <span><span class="ref-journal">Arch Neurol. </span>1984;<span class="ref-vol">41</span>:777–9.</span> [<a href="/pubmed/6331356" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6331356</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.humble.1975">Humble R, Collart M. Oligosaccharides in urines of patients with glycoprotein storage diseases. I. Rapid detection by thin-layer chromatography. Clin Chiin Acta 1975;60: 143-S. [<a href="/pubmed/1126036" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1126036</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.kawai.1985.201">Kawai H, Nishino H, Nishida Y, Yoneda K, Yoshida Y, Inui T, Masuda K, Saito S. Skeletal muscle pathology of mannosidosis in two siblings with spastic paraplegia. <span><span class="ref-journal">Acta Neuropathol (Berl). </span>1985;<span class="ref-vol">68</span>:201–4.</span> [<a href="/pubmed/4082921" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4082921</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.kjellman.1969.366">Kjellman B, Gamstorp I, Brun A, Ockerman PA, Palmgren B. Mannosidosis: a clinical and histopathologic study. <span><span class="ref-journal">J Pediatr. </span>1969;<span class="ref-vol">75</span>:366–73.</span> [<a href="/pubmed/4979627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 4979627</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.kuokkanen.2011.2651">Kuokkanen E, Riise Stensland HM, Smith W, Kjeldsen Buvang E, Van Nguyen L, Nilssen &#x000d8;, Heikinheimo P. Molecular and cellular characterization of novel alpha-mannosidosis mutations. <span><span class="ref-journal">Hum Mol Genet. </span>2011;<span class="ref-vol">20</span>:2651–61.</span> [<a href="/pubmed/21505070" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21505070</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.lund.2018.1225">Lund AM, Borgwardt L, Cattaneo F, Ardig&#x000f2; D, Geraci S, Gil-Campos M, De Meirleir L, Laroche C, Dolhem P, Cole D, Tylki-Szymanska A, Lopez-Rodriguez M, Guill&#x000e9;n-Navarro E, Dali CI, H&#x000e9;ron B, Fogh J, Muschol N, Phillips D, Van den Hout JMH, Jones SA, Amraoui Y, Harmatz P, Guffon N. Comprehensive long-term efficacy and safety of recombinant human alpha-mannosidase (velmanase alfa) treatment in patients with alpha-mannosidosis. <span><span class="ref-journal">J Inherit Metab Dis. </span>2018;<span class="ref-vol">41</span>:1225–33.</span> [<a href="/pmc/articles/PMC6326957/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6326957</span></a>] [<a href="/pubmed/29725868" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29725868</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.malm.2000.699">Malm D, Halvorsen DS, Tranebjaerg L, Sjursen H. Immunodeficiency in alpha-mannosidosis: a matched case-control study on immunoglobulins, complement factors, receptor density, phagocytosis and intracellular killing in leucocytes. <span><span class="ref-journal">Eur J Pediatr. </span>2000;<span class="ref-vol">159</span>:699–703.</span> [<a href="/pubmed/11014473" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11014473</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.malm.2008.21">Malm D, Nilssen &#x000d8;. Alpha-mannosidosis. <span><span class="ref-journal">Orphanet J Rare Dis. </span>2008;<span class="ref-vol">3</span>:21.</span> [<a href="/pmc/articles/PMC2515294/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2515294</span></a>] [<a href="/pubmed/18651971" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18651971</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.malm.2005.865">Malm D, Pantel J, Linaker OM. Psychiatric symptoms in alpha-mannosidosis. <span><span class="ref-journal">J Intellect Disabil Res. </span>2005;<span class="ref-vol">49</span>:865–71.</span> [<a href="/pubmed/16207285" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16207285</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.malm.1995.594">Malm D, Tollersrud OK, Tranebjaerg L, Mansson JE. <span><span class="ref-journal">Tidsskr Nor Laegeforen. </span>1995;<span class="ref-vol">115</span>:594–7.</span> [Alpha-mannosidosis] [<a href="/pubmed/7900112" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7900112</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.meikle.2006.307">Meikle PJ, Grasby DJ, Dean CJ, Lang DL, Bockmann M, Whittle AM, Fietz MJ, Simonsen H, Fuller M, Brooks DA, Hopwood JJ. Newborn screening for lysosomal storage disorders. <span><span class="ref-journal">Mol Genet Metab. </span>2006;<span class="ref-vol">88</span>:307–14.</span> [<a href="/pubmed/16600651" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16600651</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.meikle.1999.249">Meikle PJ, Hopwood JJ, Clague AE, Carey WF. Prevalence of lysosomal storage disorders. <span><span class="ref-journal">JAMA. </span>1999;<span class="ref-vol">281</span>:249–54.</span> [<a href="/pubmed/9918480" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9918480</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.mynarek.2012.352">Mynarek M, Tolar J, Albert MH, Escolar ML, Boelens JJ, Cowan MJ, Finnegan N, Glomstein A, Jacobsohn DA, K&#x000fc;hl JS, Yabe H, Kurtzberg J, Malm D, Orchard PJ, Klein C, L&#x000fc;cke T, Sykora KW. Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients. <span><span class="ref-journal">Bone Marrow Transplant. </span>2012;2012;<span class="ref-vol">47</span>:352–9.</span> [<a href="/pubmed/21552297" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21552297</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.noll.1989.507">Noll RB, Netzloff ML, Kulkarni R. Long-term follow-up of biochemical and cognitive functioning in patients with mannosidosis. <span><span class="ref-journal">Arch Neurol. </span>1989;<span class="ref-vol">46</span>:507–9.</span> [<a href="/pubmed/2712747" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2712747</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.poupetov_.2010.387">Poupetov&#x000e1; H, Ledvinov&#x000e1; J, Bern&#x000e1; L, Dvor&#x000e1;kov&#x000e1; L, Kozich V, Elleder M. The birth prevalence of lysosomal storage disorders in the Czech Republic: comparison with data in different populations. <span><span class="ref-journal">J Inherit Metab Dis. </span>2010;<span class="ref-vol">33</span>:387–96.</span> [<a href="/pmc/articles/PMC2903693/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2903693</span></a>] [<a href="/pubmed/20490927" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20490927</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.riise_stensland.2015.581">Riise Stensland HM, Frantzen G, Kuokkanen E, Buvang EK, Klenow HB, Heikinheimo P, Malm D, Nilssen &#x000d8;. amamutdb.no: a relational database for MAN2B1 allelic variants that compiles genotypes, clinical phenotypes, and biochemical and structural data of mutant MAN2B1 in &#x003b1;-mannosidosis. <span><span class="ref-journal">Hum Mutat. </span>2015;<span class="ref-vol">36</span>:581–6.</span> [<a href="/pubmed/25762455" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25762455</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.riise_stensland.2012.511">Riise Stensland HM, Klenow HB, Nguyen LV, Hansen GM, Malm D, Nilssen &#x000d8;. Identification of 83 novel alpha-mannosidosis-associated sequence variants: functional analysis of MAN2B1 missense mutations. <span><span class="ref-journal">Hum Mutat. </span>2012;<span class="ref-vol">33</span>:511–20.</span> [<a href="/pubmed/22161967" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22161967</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.schultz.2011.401">Schultz ML, Tecedor L, Chang M, Davidson BL. Clarifying lysosomal storage diseases. <span><span class="ref-journal">Trends Neurosci. </span>2011;<span class="ref-vol">34</span>:401–10.</span> [<a href="/pmc/articles/PMC3153126/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3153126</span></a>] [<a href="/pubmed/21723623" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21723623</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.spranger.1976.401">Spranger J, Gehler J, Cantz M. The radiographic features of mannosidosis. <span><span class="ref-journal">Radiology. </span>1976;<span class="ref-vol">119</span>:401–7.</span> [<a href="/pubmed/1265271" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1265271</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.stroobants.2017.255">Stroobants S, Damme M, Van der Jeugd A, Vermaercke B, Andersson C, Fogh J, Saftig P, Blanz J, D'Hooge R. Long-term enzyme replacement therapy improves neurocognitive functioning and hippocampal synaptic plasticity in immune-tolerant alpha-mannosidosis mice. <span><span class="ref-journal">Neurobiol Dis. </span>2017;<span class="ref-vol">106</span>:255–68.</span> [<a href="/pubmed/28720484" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28720484</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="a-mannosidosis.REF.yunis.1976.841">Yunis JJ, Lewandowski RC Jr, Sanfilippo SJ, Tsai MY, Foni I, Bruhl HH. Clinical manifestations of mannosidosis--a longitudinal study. <span><span class="ref-journal">Am J Med. </span>1976;<span class="ref-vol">61</span>:841–8.</span> [<a href="/pubmed/1008071" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1008071</span></a>]</div></li></ul></div></div><div id="a-mannosidosis.Chapter_Notes"><h2 id="_a-mannosidosis_Chapter_Notes_">Chapter Notes</h2><div id="a-mannosidosis.Author_Notes"><h3>Author Notes</h3><p>Dr Malm was the initiator of the "Troms&#x000f8; Mannosidosis Group" in 1991. He is a member of the professional advisory board of <a href="https://www.ismrd.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ISMRD</a> and the father of two children with alpha-mannosidosis.</p></div><div id="a-mannosidosis.Acknowledgments"><h3>Acknowledgments</h3><p>The authors would like to thank former ISMRD president John Forman (Hutt City, New Zealand) for valuable comments on the original manuscript.</p></div><div id="a-mannosidosis.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>18 July 2019 (aa) Revision: velmanase alfa included in Summary</div></li><li class="half_rhythm"><div>21 February 2019 (sw) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 May 2012 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>26 August 2008 (cg) Comprehensive update posted live</div></li><li class="half_rhythm"><div>25 January 2006 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>3 December 2003 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>11 October 2001 (me) Review posted live</div></li><li class="half_rhythm"><div>April 2001 (dm) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1396</span><span class="label">PMID: <a href="/pubmed/20301570" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301570</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/alpha1-a/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/xlmr/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1396&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1396/?report=reader">PubReader</a></li><li><a href="/books/NBK1396/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1396" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1396" style="display:none" title="Cite this Page"><div class="bk_tt">Malm D, Nilssen Ø. Alpha-Mannosidosis. 2001 Oct 11 [Updated 2019 Jul 18]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1396/pdf/Bookshelf_NBK1396.pdf">PDF version of this page</a> (456K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#a-mannosidosis.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#a-mannosidosis.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#a-mannosidosis.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#a-mannosidosis.Genetically_Related_Allel" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#a-mannosidosis.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#a-mannosidosis.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#a-mannosidosis.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#a-mannosidosis.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#a-mannosidosis.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#a-mannosidosis.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#a-mannosidosis.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4125[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">MAN2B1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Variations in ClinVar</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NBK1396+AND+genereviews[submitter]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Variations from this GeneReview in ClinVar</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1469304" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1469304" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1469304" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1469304" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301341" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mucopolysaccharidosis Type I</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mucopolysaccharidosis Type I<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Clarke LA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301446" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gaucher Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gaucher Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pastores GM, Hughes DA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/18651971" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alpha-mannosidosis.</a><span class="source">[Orphanet J Rare Dis. 2008]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Alpha-mannosidosis.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Malm D, Nilssen Ø. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Orphanet J Rare Dis. 2008 Jul 23; 3:21. Epub 2008 Jul 23.</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/23844448" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mucopolysaccharidosis Type IVA</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Mucopolysaccharidosis Type IVA<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Regier DS, Oetgen M, Tanpaiboon P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301428" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cystic Fibrosis and Congenital Absence of the Vas Deferens</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Cystic Fibrosis and Congenital Absence of the Vas Deferens<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Ong T, Marshall SG, Karczeski BA, Sternen DL, Cheng E, Cutting GR. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301570" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301570" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040f8475f66d18aabd483c">Alpha-Mannosidosis - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Alpha-Mannosidosis - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:40:20-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal105&amp;ncbi_phid=CE8CCF1BE04015410000000005E901F8&amp;ncbi_session=CE8CCF1BE040F831_1513SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1396%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1396&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1396/&amp;ncbi_pagename=Alpha-Mannosidosis - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8CCF1BE040F831_1513SID /projects/books/PBooks@5.22 portal105 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>